A5035586844- Inflammatory Bowel Disease
- Microscopic Colitis
- Renal Transplantation Outcomes and Treatments
- Biosimilars and Bioanalytical Methods
- Pharmacological Effects of Natural Compounds
- Plasma Applications and Diagnostics
- Pregnancy and Medication Impact
- Pneumocystis jirovecii pneumonia detection and treatment
- Diagnosis and treatment of tuberculosis
- Neurological Complications and Syndromes
- Organ Transplantation Techniques and Outcomes
- Tuberculosis Research and Epidemiology
- Cytomegalovirus and herpesvirus research
- Metabolism and Genetic Disorders
- Glycogen Storage Diseases and Myoclonus
- Lipoproteins and Cardiovascular Health
- Renal and Vascular Pathologies
- Polyomavirus and related diseases
- Helicobacter pylori-related gastroenterology studies
- Colorectal Cancer Treatments and Studies
- Renal Diseases and Glomerulopathies
- Rheumatoid Arthritis Research and Therapies
- Autoimmune and Inflammatory Disorders Research
- HIV/AIDS drug development and treatment
- Adolescent and Pediatric Healthcare
Pfizer (United States)
2016-2025
Weizmann Institute of Science
2025
Drexel University
2006-2024
Brigham and Women's Hospital
2020
Harvard University
2020
Mass General Brigham
2020
Foundation for the National Institutes of Health
2020
Novartis (France)
2010
California Institute for Regenerative Medicine
2004-2006
Ben-Gurion University of the Negev
2006
Tofacitinib, an oral, small-molecule Janus kinase inhibitor, was shown to have potential efficacy as induction therapy for ulcerative colitis in a phase 2 trial. We further evaluated the of tofacitinib and maintenance therapy.
Adjusted-dose warfarin is highly efficacious for prevention of ischaemic stroke in patients with atrial fibrillation (AF). However, this treatment carries a risk bleeding and the need frequent medical monitoring. We sought an alternative that would be safer easier to administer AF who are at high-risk thromboembolism.1044 least one thromboembolic factor (congestive heart failure or left ventricular fractional shortening < = 25%, previous thromboembolism, systolic blood pressure more than 160...
Background & AimsTofacitinib is an oral, small-molecule inhibitor of JAK approved in several countries for the treatment ulcerative colitis (UC). We report integrated safety analyses tofacitinib-treated patients with moderate to severe UC.MethodsPatients receiving placebo or tofacitinib (5 10 mg) twice daily were analyzed as 3 cohorts: induction (phase 2 and studies, n = 1220), maintenance study, 592), overall (patients 5 mg phase 2, 3, open-label, long-term extension 1157; 1613...
Tofacitinib is an oral, small molecule inhibitor of JAK for the treatment ulcerative colitis (UC). We evaluated onset symptom improvement in post-hoc analyses data from 2 phase 3 trials induction therapy with tofacitinib patients UC (OCTAVE Induction 1 and 2).The studies comprised moderate to severe active who were intolerant to, or failed by previous with, corticosteroids, thiopurines, and/or tumor necrosis factor (TNF) antagonists. Patients received (10 mg twice daily, n = 905) placebo (n...
Tofacitinib is an oral, small molecule Janus kinase [JAK] inhibitor that being investigated for ulcerative colitis [UC]. We evaluated health-related quality of life [HRQoL] in tofacitinib UC Phase 3 studies.Patients ≥ 18 years old OCTAVE Induction 1 [N = 598] and 2 541] with moderately to severely active were randomised [1:4] placebo or 10 mg twice daily [BID] 8 weeks. Subsequently, Sustain re-randomised [1:1:1] clinical responders 593] from induction studies placebo, 5 BID, 52 Inflammatory...
We evaluated a panel of novel urinary and serum biomarkers (BMs) for early sensitive detection cisplatin drug-induced kidney injury (DIKI) in patients with cancer, comparing their diagnostic accuracy standard BMs (SBMs). In this prospective exploratory observational study, 105 treated ("treated" > 65 mg/m2/cycle), 20 non-cisplatin cancer controls ("nontreated"), 34 "healthy" were enrolled. The group's urine samples collected predose, after 12 hours, on days 1, 2, 4, 7, 14, 21. SBMs (NBMs; 8...
A number of factors have been implicated in decreasing long-term renal graft survival. Factors such as living versus cadaveric donor status, acute rejection, and HLA matching studied detail. Mild obesity defined a body mass index (BMI) >25 has found to deleterious effect on physiologic processes. We the BMI transplantation outcome.A total 405 patients who underwent at Saint Barnabas Medical Center from 1990 1997 were evaluated. All known variables impacting function collected. Multivariate...
Mycophenolate mofetil (MMF) is commonly used in solid organ transplant recipients. MMF converted to mycophenolic acid (MPA) upon reaching the systemic circulation. Many acidic drugs have altered protein binding renal failure, and it possible that MPA may be decreased. The authors studied 23 recipients: 8 patients (7 kidney, 1 kidney/pancreas) with chronic insufficiency (CRI) 15 preserved function. Plasma was obtained for kinetic profiles of total MPA, free its glucuronide metabolite (MPAG)....
Abstract The origin of MXene's excellent electromagnetic shielding performance is not fully understood. MXene films, despite being inhomogeneous at the nanometer scale, are often treated as if they compared to bulk conductors. It reasonable wonder treatment a homogeneous material remains valid very small film thickness and it depends on interlayer spacing. goal present work test model applicable nanometer‐thin Ti 3 C 2 T x films and, so, investigate how parameters may depend variations in...
Although multiple studies of demographic variables have been associated with allograft thrombosis, these results are not routinely reproducible. Are ESRD patients hypercoagulable states (HCS) (antithrombin III deficiency, protein S or C activated resistance, and anticardiolipin antibodies) at predictably greater risk for thrombosis?Between 1996 1999, all renal transplant candidates were screened hypercoagulability factors [HRF] (multiple arteriovenous access thromboses, prior deep vein...
Purpose: The frequency, onset, mechanisms, and causes of dyslipidemia after renal transplantation are reviewed in the context adverse impact lipid alterations, recent guidelines, available treatment options. Summary: At least 60% adult transplant recipients develop dyslipidemia, which occurs within one month initiation immunosuppressive therapy continues indefinitely unless treated. Cyclosporine, sirolimus, prednisone mainly implicated, profile differs between individual agents. In...
Fabry's disease is an X-linked error of glycosphingolipid metabolism. Clinical manifestations the are secondary to accumulation glycosphingolipids in various tissues. Renal failure and vascular complications common. There conflicting reports regarding outcomes patients with after renal transplantation.We reviewed United States Data System Registry database from 1988 1998, found 93 who had received a transplant. Case-matched were identified serve as controls.Patients demonstrated equivalent...
Background. It has been well documented that a regimen of mycophenolate mofetil (MMF), cyclosporine (CsA), and prednisone (Pred) reduces the incidence acute rejection in renal transplant recipients, as compared with previous regimens based on azathioprine (AZA), CsA, Pred. In general patient population, immunosuppressive include MMF are usually tolerated. is not clear whether this holds true for older who may be more susceptible to complications from greater immunosuppression conferred by...
Tofacitinib is an oral, small molecule JAK inhibitor for the treatment of ulcerative colitis. We report integrated analyses infections in Phase [P]2 and P3 OCTAVE programmes. Three cohorts were analysed: Induction [P2/3 induction studies]; Maintenance [P3 maintenance study]; Overall [all tofacitinib-treated patients induction, maintenance, or ongoing, open-label, long-term extension studies; as May 2019]. Proportions incidence rates [IRs; unique with events/100 patient-years] serious [SIs],...
Abstract Drug-induced kidney injury (DIKI) is of significant concern, both during drug development and in clinical practice. We report a patient-centric approach for implementation the FDA-qualified safety biomarker panel, highlighting Phase 1 2 trials candidate therapeutics Pfizer’s portfolio (PFE-1 PFE-2, respectively) that induced tubular rat toxicity studies. Clusterin (CLU), cystatin-C (CysC), molecule-1 (KIM-1), N-acetyl-beta-d-glucosaminidase (NAG), neutrophil gelatinase-associated...
Patients with ulcerative colitis (UC) are at elevated risk of cardiovascular disease vs the general population, despite a lower prevalence traditional factors, including hyperlipidemia. Mechanistic studies in patients rheumatoid arthritis and psoriasis suggest that tofacitinib restores serum lipids to preinflammation levels by reversing inflammation-induced cholesterol metabolism changes. We reviewed data on lipid events, alongside recommendations for managing during treatment UC, based...
Tofacitinib is an oral, small molecule Janus kinase inhibitor for the treatment of ulcerative colitis (UC). We present integrated analyses nonmelanoma skin cancer (NMSC) incidence in tofacitinib UC clinical program.Nonmelanoma events were evaluated from 3 randomized, placebo-controlled studies: 2 identical, 8-week induction studies (NCT01465763, NCT01458951), a 52-week maintenance study (NCT01458574), and open-label, long-term extension (NCT01470612). Cohorts analyzed were: Induction,...